I have always enjoyed our conversations and this one is no different.
For the record, Kim's 20.24 second time was sans exaserbation - it was pretty much in-line for where she was at the the time. I do have video of her 59 second walk that we did a few weeks later when she was going through her very first major bacterial die-off. She needed trekking poles for that. I don't talk about that walk anywhere because it was so "outside of the box". But, she was greatly inflammed like an exaserbation, however, unlike an exaserbation, she came out of it walking better. That's sorta my point. Over one year, there have been bumps that are relapse like, but they are from heavy bacterial die-off related inflammation, not exaserbation inflamation. There have been 4 such episodes in the last year - all documented in my ABX thread. Following each one, Kim improved, rather then losing something.
I do accept that it's possible that some don't have bacterially caused MS, but in Kim's case, the impact has been striking.
I understand that a clinical setting is needed. But, if Kim and I waited for ABX to get FDA approved, she'd be in a wheelchair at best. We looked at everything we could find, including anecdotal evidence from many here and we figured that it helped some, but did not result in harm - so there was nothing to lose and everything to potentialy gain. I feel that you made a similar calculation with Tovaxin - which you know I was very much hoping would happen in a big way. I bet on Tovaxin in a different way.
So for us it was simple, low risk, low cost, big potential outcome - the biggest part of the investment was dedication. Die off is a lot like an exaserbation, so you have to have confidence in what you are doing to be on ABX. Both are inflammation. Both leave you feeling similarly lousy. The only difference is what's actually being killed, bacteria instead of myelin. The bacteria resides near the areas where your myelin has been impacted so, it should make sense the inflammation there will give you similar side-effects. It's just that the overall results are different.
I know many will wait. Dr. Sriram is in the middle of a 3 year trial. So then there will need to be another trial and another. Meanwhile, Kim has control of her bladder again. It may be anecdotal, but for Kim it sure counts that she don't need to wear pee pads anymore.
So, Kim and I are very happy about this and I just want to be able to share this with others in hopes that it just might help someone else. even if We can help just one other person who has MS find relief this way, it will have been worth the hours I spend here sharing Kim's path to improved health and function.
I don't know how much more proof Kim and I need than what we have experienced first hand. But Pneumonia is not geographically distributed evenly and it does, if I recall correcty, have a lower infection rate in warmer climate because the bacteria doesn't live as well outside the body in warmer climate. Bacterial infection also can tie into the Faroe Island example. I also think ....... given the stuff that doctors need to do before they give the MS diagnosis .... think about it, no one walked into the physician and got a blood test or peed in a cup and was told they had MS. More likely there were multiple appointments with multiple professionals and sereral test that might have been costly. Given this, I don't think everyone that has MS around the world is diagnosed, or they also might die of something else first before anyone could figure out why they couldn't walk so well.
I do not mean to say or suggest that I have a complete explanation for MS as a bacterial pathology. I'm not qualified now nor wealthy enough to fund such research. However, In order to introduce a new and FUNCTIONING approach, I have to start somewhere. So why not here? What better thing to share at TIMS than soemthing that significantly helped you oversome the progressive impact of MS? Ken
It would be really nice to be able to put links in here
If I have included a bad link, google the word "Scholar", click link for "Google Scholar". Search for the name of the paper and author in Google Scholar.